Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China

And UK Government Teams Up With Wockhardt

The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.

Coronavirus globe
• Source: Shutterstock

BioNTech SE and partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. have dosed the first 72 participants in a Phase I trial in China with BioNTech’s nucleoside-modified messenger RNA coronavirus vaccine candidate BNT162b1, following the approval of an IND by the National Medical Products Administration last month.

The two companies are jointly developing the vaccine in China under a $135m alliance signed in March covering mainland China,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip